Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
Hosted on MSN8h
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational ...
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
bovnews14h
Vir Biotechnology Inc (VIR) Stock: Surpassing Expectations in the Market?
JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...
Vir Biotechnology (VIR) Gets a Buy from Barclays
In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...
Vir Biotechnology Reports Promising Trial Results for Cancer Therapies
Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...
Vir Biotechnology, Once a Hot Covid Stock, Finds New Path Forward in Cancer
Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the ...
bovnews1d
Vir Biotechnology (VIR) Makes Big Waves: Why Today’s Stock Surge Matters
Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...
Vir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties
Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...